No profile data available.
Kiniksa Pharmaceuticals International, plc (KNSA) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in London, United Kingdom, with about 366 full-time employees.
It reported revenue of $677.56 million for fiscal year 2025, up 60.1% from fiscal year 2024, and net income of $59.01 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $243.60 million, up 55.4% from a year before. United States was its largest region in fiscal year 2025, with 100% of revenue. Its market capitalization was $6.14 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Kiniksa Pharmaceuticals International reported $677.56 million in revenue for fiscal year 2025, up 60.1% from $423.24 million in fiscal year 2024. In Q2 2026 revenue was $243.60 million.
United States: 100% of revenue by region in fiscal year 2025, followed by United Kingdom (under 1%).
$6.14 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include TG Therapeutics, Inc. (TGTX), Immunovant, Inc. (IMVT), Aurinia Pharmaceuticals Inc. (AUPH), Viridian Therapeutics, Inc. (VRDN).